About Scientari
Explore. Analyze. Decide.About Scientari
Scientari’s founder, Christopher Hoover, has spent three decades taking complex life-science and deep-tech platforms to market — the early commercial person who learns a new technology domain fast, figures out how to position it, and builds the infrastructure that turns science into revenue.
That pattern is the reason Scientari exists. Three decades of genomics data, clinical development, and pharma business development now converge in a single ecosystem of intelligence platforms and decision tools.
Genomics data, at scale and early
Hoover launched his career with Invitrogen in 1989 — then a 20-person startup — and helped it grow into a publicly traded company of 2,700 employees. His mandate was to make a small company compete like a major one: build sales and marketing impact that projected the reach and professionalism of a far larger competitor while holding headcount and cost down.
Invitrogen.com was one example. Launched with a full product catalog in the early ’90s — before most life-science companies had any web presence, it was among the earliest e-commerce systems in any industry. By 2000 it carried over 10,000 documents, integrated databases for citations and technical support, BLAST homology search across a 6,000-product clone library, and a direct tie into NIH electronic purchasing. The infrastructure drove millions in sales without a matching expansion of sales and support staff.
He went on to help commercialize FPGA-accelerated genomics across multiple companies — specialized silicon that brought massive speedups to DNA sequence comparison, much the way GPUs accelerate AI today. The systems made computationally exhaustive searches tractable when most groups had to fall back on heuristics, and in the pre-cloud era were frequently the only viable way to run genome-scale pipelines. They sold into pharma, agricultural genomics, as well as government research programs across Asia and Europe.
That work built an early, hands-on understanding of large biological datasets and the compute burdens behind them — the foundation Scientari’s scoring platforms rest on today.
Clinical development, where protocols cost years
Hoover led the U.S. launch of MedinCell (Euronext: MEDCL) as CEO of its U.S. subsidiary, building a San Diego formulation lab that ran multi-million-dollar programs and drove a major share of global revenue from a fraction of total R&D staff.
He led business development and global marketing across animal health and human-pharmaceutical and drug delivery combination programs, including surgically placed controlled-release depots for orthopedic and intra-articular applications, one of which advanced to late-stage clinical trials. The platform commercialized during this period yielded an FDA-approved product about a decade later.
This is the world TrialReadiness was built for: clinical development, where the cost of a misaligned protocol is measured in years and millions.
Pharma business development, on the buyer’s side of the table
As part of QIAGEN Digital Insights, he represented omics software and biomedical knowledge-base products to the top 20 pharmaceutical accounts for biomarker discovery, drug discovery, and drug repurposing, and developed commercial models for licensing knowledge bases to tech-bio companies.
That work placed him directly in the drug-repositioning intelligence conversation with the exact buyers Repothesis now serves — and gave him a front-row view of which “AI drug discovery” claims held up under technical scrutiny and which didn’t. That judgment is what the AI-Native Biotech Tracker is built on.
Adjacent ground
Across these roles he also helped launch a digital health platform, worked in animal and digital health (IoT monitoring, machine-learning video analysis of behavior for richer preclinical data), marketed RFID solutions for anti-counterfeiting solutions, and worked in the energy sector on plasma-based reforming of natural gas for hydrogen production — the last of which, along with the FPGA work, feeds Scientari’s strategy guides.
He has made several angel investments in early-stage life-science and deep-tech companies and held equity in ventures he helped build, including several that reached public markets or were acquired.
Scientari LLC builds market intelligence, strategy guides, and decision platforms for professionals in biopharma, genomics, energy technology, and computing.
Explore, Analyze, Decide.